Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.

Product Highlight – Dukoral

12 Jul 2017
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics

The Drinkable Vaccine against Cholera & enterotoxigenic E.coli (ETEC) Diarrhoea


Clinically proven protective efficacy:
- Up to 85-90% against cholera in the first 6 months3,4,6
- Up to 67% against ETEC in the first 3 months.5

At least one week interval between doses. Primary immunization can be completed as early as 8 days for adults and children over 6 years old (2 required doses) and 15 days for children 2-6 years (3 required doses).1

Onset of protection starts 7 days after completion of immunisation. The vaccination course should be completed at least one week before traveling.1

Good safety profile with most frequently reported adverse reactions occurred at similar frequencies in vaccine and placebo group in studies.

References:

1. DUKORAL full prescribing information (SV40398_MY).
2. Clements JD, Finkelstein RA. Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect Immun 1978;22:709–13.
3. World Health Organization. Use of Oral Cholera Vaccine in Humanitarian Emergencies. http://www.who.int/cholera/vaccines/OCV_in_humanitarian_emergencies_15Jan2014.pdf.
4. Clemens JD, Sack DA, Harris RJ et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986, 2:124-7.
5. Clemens JD., et al. Cross-protection by B subunit whole-cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: result of a large-scale field trial. J Infect Dis 1988; 158:372-77.
6.
World Health Organization. Cholera vaccines WHO position paper. Weekly Epidemiologic Record (WER). No 13, 2010, 85, 117-128 http://www.who.int/wer/2010/wer8513.pdf.

Further information is available in section 12b, New in This Issue and mims.com
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.